Three different models of continuous manufacturing are described in the draft guideline. The guideline incorporates the ICH Q7 definition of a batch to continuous manufacturing.
The acquisition includes Teneobio's proprietary bispecific and multispecific antibody technologies, which will enable significant acceleration and efficiency in the discovery and development of new molecules.